TAVI vs SAVR for Severe Aortic Stenosis: How Doctors Choose the Right Valve Replacement
If you or a loved one has been diagnosed with severe aortic stenosis—narrowing of the aortic valve—you are likely trying to understand two treatment options: TAVI, a catheter-based valve replacement, and SAVR, traditional surgical aortic valve replacement. Both replace the diseased valve. The right choice depends on the severity of the disease, symptoms, valve anatomy, age, surgical risk, associated heart conditions and, increasingly, how the patient's valve treatment may evolve over a lifetime.
Medically reviewed by: Dr. Arvind Singh, Senior Interventional and Structural Cardiologist and Dr. Sudhir Adalti, Senior Cardiothoracic & Vascular Surgeon, Apollo CVHF Hospital, Ahmedabad
Step 1: Confirming Severe Aortic Stenosis
Aortic stenosis occurs when the aortic valve becomes narrowed, making it harder for blood to leave the left ventricle and reach the rest of the body.
In older adults, degenerative calcification is the most common cause. Bicuspid aortic valve and rheumatic valve disease are other important causes, particularly in younger patients or specific populations.
The severity of aortic stenosis is primarily assessed using echocardiography. Important measurements include:
Peak transvalvular velocity
Mean transvalvular gradient
Aortic valve area
Left ventricular function
Symptoms are equally important.
Severe aortic stenosis can cause:
Breathlessness, particularly on exertion
Reduced exercise tolerance
Chest discomfort
Dizziness
Fainting or near-fainting
Once severe aortic stenosis becomes symptomatic, aortic valve replacement is generally recommended, provided the patient has a meaningful expected survival and the intervention is appropriate.
Untreated symptomatic severe aortic stenosis carries a poor prognosis, which is why timely assessment is important.
The 2025 ESC/EACTS guidelines also recognise selected circumstances in which intervention may be considered before symptoms develop, based on factors such as left ventricular function, exercise testing, biomarkers and other high-risk features. This is a Heart Team decision rather than a routine approach for every asymptomatic patient.
Step 2: What Tests Are Usually Needed?
Before TAVI or SAVR is planned, the Heart Team needs a detailed understanding of both the valve and the patient's overall health.
Echocardiography
Echocardiography establishes the severity of aortic stenosis and assesses:
Valve opening and haemodynamics
Left ventricular ejection fraction
Heart chamber size
Other valve abnormalities
Pulmonary pressures
Other structural abnormalities
In selected patients, transesophageal echocardiography may provide additional anatomical information.
Apollo CVHF provides 2D, 3D and advanced echocardiography.
CT assessment
Cardiac CT is particularly important when TAVI is being considered.
It provides detailed information about:
Aortic annulus dimensions — important for selecting the appropriate transcatheter valve size
Coronary ostial height — relevant to the risk of coronary obstruction during TAVI
Aortic root and ascending aorta anatomy
Calcium distribution and burden — important for valve expansion, sealing and procedural planning
Vascular access — particularly the femoral arteries for transfemoral TAVI
Valve morphology — including tricuspid versus bicuspid anatomy
CT can also provide useful information for surgical planning, but the CT assessment required for TAVI is particularly detailed because the transcatheter valve must be matched precisely to the patient's anatomy.
Apollo CVHF provides CT coronary angiography.
Coronary assessment
Significant coronary artery disease can coexist with severe aortic stenosis.
Depending on the patient's symptoms, risk profile and clinical situation, coronary assessment may involve coronary angiography or non-invasive testing.
This is important because significant coronary disease may influence whether TAVI or SAVR is the better overall strategy and whether coronary revascularisation is required.
Other assessment
The Heart Team may also consider:
ECG
Blood tests, including kidney function and haemoglobin
Frailty
Other medical conditions
Previous cardiac procedures
Functional status
Life expectancy
Patient preferences
The decision is therefore based on more than age or symptom severity alone.
Step 3: The Heart Team Decision
The decision between TAVI and SAVR is increasingly based on a Heart Team approach.
A structural or interventional cardiologist and cardiac surgeon assess the patient's clinical condition, imaging, surgical risk and long-term treatment options together.
Surgical risk scores such as STS-PROM or EuroSCORE II may contribute to the assessment, but they are not used in isolation.
The 2025 ESC/EACTS guidelines have refined the approach to TAVI versus SAVR, placing greater emphasis on:
Age
Life expectancy
Surgical and procedural risk
Valve anatomy
Vascular access
Associated coronary or aortic disease
Future valve interventions
Patient preference
What do the current guidelines say?
For tricuspid aortic stenosis:
| Patient profile | General guideline approach |
|---|---|
| Age ?70 years, anatomically suitable for transfemoral TAVI | TAVI is recommended as the primary treatment modality |
| Age <70 years with low surgical risk | SAVR is generally preferred |
| Other patients | Individualised Heart Team decision |
| Unsuitable for surgery | TAVI may be appropriate when anatomy and access permit |
| Bicuspid aortic valve | Anatomy requires particularly careful assessment; SAVR remains important, especially in younger patients or when associated aortic disease is present |
The 2025 guidelines therefore moved the age threshold at which TAVI is generally preferred in anatomically suitable patients with a tricuspid aortic valve from the older 75-year framework to 70 years.
This does not mean that every patient aged 70 or older should automatically receive TAVI.
Age is one part of a broader decision that includes anatomy, life expectancy, procedural risk, future coronary access and the possibility of future valve interventions.
Step 4: Choosing the Valve — A Decision That Lasts Beyond the Procedure
Choosing between TAVI and SAVR is only part of the decision.
The type of replacement valve also matters because it influences long-term management.
Tissue valves
Bioprosthetic or tissue valves are used in both TAVI and SAVR.
They avoid the lifelong anticoagulation requirement associated with mechanical valves, although patients may still require anticoagulation for another reason, such as atrial fibrillation.
Bioprosthetic valves can eventually develop structural valve deterioration.
The durability of surgical bioprosthetic valves is well established over longer periods. Long-term durability data for transcatheter valves, particularly in younger patients, continue to mature.
Mechanical valves
Mechanical valves are available through surgical valve replacement, not TAVI.
Their major advantage is excellent long-term durability.
Their major trade-off is the requirement for lifelong warfarin anticoagulation and regular monitoring.
This makes mechanical valves an important consideration in selected younger patients, particularly when long-term durability is prioritised and lifelong anticoagulation is acceptable.
Lifetime Valve Planning
Aortic valve replacement should not always be viewed as an isolated procedure.
For a younger patient, the question may be:
What is the best valve strategy not only today, but over the next several decades?
A patient receiving a tissue valve may eventually develop valve degeneration and require another intervention.
In selected patients, a future valve-in-valve TAVI may be possible when a surgical or transcatheter bioprosthetic valve fails.
However, valve-in-valve treatment is not automatically suitable for every patient. Factors such as the original valve size, coronary anatomy, patient-prosthesis mismatch and future coronary access need to be considered from the beginning.
This is one reason lifetime management is increasingly part of the initial Heart Team discussion.
Why SAVR Remains an Important Option
TAVI has transformed the treatment of severe aortic stenosis, but surgery remains an important and sometimes preferable option.
1. Other cardiac surgery can be performed at the same time
If a patient also requires:
Coronary artery bypass surgery
Another valve procedure
Aortic root or ascending aortic surgery
SAVR can allow these problems to be addressed during the same operation.
2. Mechanical valve replacement is possible
A mechanical valve can only be implanted surgically.
This may be an important consideration for selected younger patients who prioritise durability and accept lifelong warfarin therapy.
3. Some anatomy is better suited to surgery
Bicuspid aortic valve anatomy, associated aortic disease, unfavourable valve morphology or other anatomical factors may make SAVR preferable.
The 2025 ESC/EACTS guidelines continue to place an important role for SAVR in younger patients and in many patients with bicuspid aortic stenosis.
What are the risks of TAVI?
TAVI avoids open-heart surgery and is generally associated with a faster recovery, but it is not risk-free.
Potential complications include:
Vascular access complications
Bleeding
Stroke
Need for permanent pacemaker
Paravalvular aortic regurgitation
Acute kidney injury
Rare coronary obstruction
Valve-related complications
The risk of requiring a permanent pacemaker is influenced by the type of valve, implantation depth and the patient's underlying conduction system.
What are the risks of SAVR?
Surgical aortic valve replacement is a major cardiac operation.
Potential complications include:
Bleeding
Infection
Stroke
Arrhythmias
Kidney injury
Complications related to general anaesthesia and cardiopulmonary bypass
Myocardial infarction or other cardiovascular complications
Longer recovery associated with sternotomy
The individual risk varies considerably according to age, surgical risk, other medical conditions and the complexity of the operation.
Therefore, it is not accurate to describe TAVI as universally safer than surgery—or SAVR as universally more durable and therefore better.
The comparison has to be made for the individual patient.
TAVI vs SAVR: Recovery
The recovery timelines are different.
TAVI
Many patients can sit up and walk relatively soon after the procedure and may be discharged within a few days.
Some patients may require a longer hospital stay because of age, frailty, kidney function, rhythm disturbances, vascular complications or other medical issues.
SAVR
Surgical valve replacement generally requires a longer hospital stay and recovery period.
When a sternotomy is performed, the breastbone requires time to heal. Heavy lifting and strenuous pushing or pulling are restricted during the early recovery period, with gradual return to normal activity under the surgical team's guidance.
In both cases, recovery of energy and exercise capacity may take longer than the hospital stay itself.
Cardiac rehabilitation can be useful for appropriate patients following either procedure.
TAVI in Bicuspid Aortic Valve
Bicuspid aortic valve requires particular attention.
Unlike a normal tricuspid aortic valve, a bicuspid valve has two functional leaflets and often has an associated aortopathy.
Bicuspid anatomy can present challenges for TAVI because of:
Asymmetric calcium
Elliptical annular anatomy
Calcified raphe
Aortic root or ascending aortic dilatation
Different patterns of valve morphology
TAVI is increasingly used in carefully selected bicuspid patients, particularly when surgical risk is increased and the anatomy is favourable.
However, evidence is less extensive than for tricuspid aortic stenosis because many landmark TAVI trials excluded or underrepresented patients with bicuspid valves.
SAVR remains particularly important in younger patients with bicuspid aortic stenosis, associated aortic disease or unfavourable valve anatomy.
Why the CT Scan Matters So Much Before TAVI
A TAVI valve is deployed inside the patient's existing aortic valve.
This means the anatomy has to be understood in three dimensions before the procedure.
The CT assessment helps the Heart Team determine:
Which valve size is appropriate
Whether transfemoral access is feasible
How close the coronary arteries are to the valve
Where calcium is distributed
Whether the aortic root is suitable
How the prosthetic valve is likely to interact with the native anatomy
Whether future coronary access is likely to be straightforward
For TAVI, the CT scan is not simply another investigation—it is a central part of procedural planning.
Aortic Stenosis and Coronary Artery Disease
Aortic stenosis and coronary artery disease frequently coexist, particularly in older patients.
This creates another important consideration when choosing TAVI or SAVR.
If significant coronary artery disease requires bypass surgery, SAVR combined with CABG may sometimes be preferable to TAVI followed by separate coronary intervention.
Conversely, a patient without significant coronary disease may be an excellent candidate for isolated TAVI when the anatomy is suitable.
This is another example of why the treatment decision cannot be based on the valve alone.
A Note from Dr. Arvind Singh and Dr. Sudhir Adalti
We evaluate these cases jointly because the decision between TAVI and SAVR genuinely depends on details that cannot be captured by age alone.
The echocardiogram establishes the severity and physiological consequences of the valve disease.
The CT scan provides detailed information about the valve, aortic root, coronary arteries and vascular access.
The clinical assessment determines surgical risk, frailty, associated disease, life expectancy and the patient's priorities.
The final decision is therefore based on the complete picture, rather than a single test or a single age cutoff.
Apollo CVHF Hospital's Role in Aortic Valve Care
Apollo CVHF Hospital, Ahmedabad, brings structural cardiology and cardiac surgery together for the evaluation and treatment of severe aortic stenosis.
Relevant services include:
Patients are evaluated according to their individual valve anatomy, clinical condition, surgical risk and long-term treatment needs.
Frequently Asked Questions
Does age alone decide whether I get TAVI or surgery?
No.
Age is an important part of the current guideline framework, but it is not the only factor.
For patients aged 70 years or older with tricuspid aortic stenosis and suitable anatomy, TAVI is generally recommended as the primary treatment approach.
For patients younger than 70 years who have low surgical risk, SAVR is generally preferred.
Patients outside these groups require an individualised Heart Team assessment that considers anatomy, surgical risk, life expectancy, associated disease, future valve procedures and patient preference.
If I get a tissue valve now, will I need another procedure later?
Possibly.
Tissue valves can deteriorate over time. The long-term durability of surgical bioprosthetic valves is better established than that of transcatheter valves in younger patients.
If a tissue valve eventually fails, a valve-in-valve TAVI may be possible in selected patients.
Whether this will be feasible depends on the original valve, anatomy, coronary position, valve size and other factors.
Do I need to be on blood thinners for life after valve replacement?
Not necessarily.
A mechanical valve requires lifelong warfarin anticoagulation.
A tissue valve does not generally require lifelong anticoagulation solely because it is a tissue valve. However, a patient may still require anticoagulation for another condition, such as atrial fibrillation.
The antithrombotic plan should therefore be individualised.
Can TAVI be performed in a bicuspid aortic valve?
Yes, in selected patients.
However, bicuspid anatomy is more complex and requires detailed CT assessment.
SAVR remains particularly important for younger patients, patients with associated aortic disease and those with unfavourable anatomy for TAVI.
Why would someone choose surgery if they qualify for TAVI?
Surgery may offer advantages when:
Coronary bypass is also required
Another valve requires surgery
The ascending aorta or aortic root requires treatment
A mechanical valve is preferred
The valve anatomy is unsuitable for TAVI
Lifetime management considerations favour SAVR
TAVI is not simply the less invasive version of SAVR. They are different treatment strategies with different short- and long-term considerations.
Is TAVI always safer than SAVR?
No.
TAVI is less invasive and generally offers faster recovery, but it has its own complications, including vascular complications, paravalvular leak and pacemaker implantation.
SAVR carries the risks of major surgery but offers advantages in certain anatomical and clinical situations.
The relevant question is not which procedure is universally safer, but which procedure offers the best balance of risk and benefit for this particular patient.
Talking to a Specialist
If you have been diagnosed with severe aortic stenosis or have symptoms such as breathlessness, chest discomfort, dizziness or fainting, evaluation by a structural cardiologist and cardiac surgeon can help determine the most appropriate treatment.
The assessment generally combines:
Clinical evaluation
Echocardiography
CT imaging
Assessment of surgical risk
Evaluation of coronary disease
Consideration of valve durability
Expected life expectancy
Patient preferences
Planning for possible future interventions
For complex cases, a Heart Team approach helps ensure that TAVI and SAVR are considered together rather than as isolated specialties.
The Bottom Line
TAVI and SAVR are both established treatments for severe aortic stenosis. Neither is universally better.
For an older patient with a tricuspid valve and suitable anatomy, TAVI may offer an excellent balance of safety, recovery and long-term outcomes.
For a younger patient with low surgical risk, SAVR may remain preferable, particularly when lifetime valve management, durability, bicuspid anatomy or associated cardiac disease is important.
The final decision should be based on the valve, the patient and the years of cardiovascular care that follow the procedure—not simply the procedure that is easiest to perform today.
Medical Review
Medically reviewed by: Dr. Arvind Singh, Senior Interventional and Structural Cardiologist, and Dr. Sudhir Adalti, MS, MCh (CTVS), Senior Cardiothoracic & Vascular Surgeon, Apollo CVHF Hospital, Ahmedabad.
Last reviewed: October 2026
Last updated: October 2026
References
Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2025;46:4635–4736.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143–e227.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine. 2016;374:1609–1620.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. New England Journal of Medicine. 2019;380:1695–1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis in Low-Risk Patients. New England Journal of Medicine. 2019;380:1706–1715.
Medical Disclaimer
This article is intended for general educational purposes and does not replace individualised medical advice.
Treatment decisions for aortic stenosis depend on the patient's symptoms, echocardiographic findings, valve anatomy, CT assessment, surgical risk, associated cardiovascular disease, life expectancy and individual preferences. A qualified cardiologist and cardiac surgeon should assess each patient before a treatment decision is made.
